Solid stock: buy or sell?

SLDB stock price: $5.14 -2.10% At close on July 16th, 2019

Updated on:
July 16th, 2019

0

Solid shares fell -2.10% to $5.14 today. On Thursday SLDB plunged a spooky -6.87%. On July 9th SLDB boosted an astounding 5.56%.

Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States.

Should I buy Solid stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Solid stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Solid stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we collected 5 ratings published for SLDB stock in the last 30 days.

The general sentiment of these ratings is bearish for SLDB stock, with 2 negative ratings.
Is SLDB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-14Goldman Sachs GroupNeutralSell
2019-5-14Credit Suisse GroupNeutralUnderperform
2019-2-8Svb LeerinkOutperformMarket Perform
2019-2-8CitigroupSellNeutral
2019-2-7Chardan Capitaln/aBuy

Solid stock analysis

Daily outlook

Solid Biosciences fell a rough -2.10% and closed at $5.14.

Solid shares fell -2.10% to $5.14 today.

SLDB stock chart (daily)

Weekly outlook

Shares of Solid Biosciences dropped a rough -3.20% this week. Late June SLDB rocketed a super good 12.87% in just one week. Early July SLDB collapsed a frightening -10.79% in just one week.

SLDB stock chart (weekly)

Solid stock price history

Solid stock went public on January 26th, 2018 with a price of $25.501. Since then, SLDB stock sliced a -79.80%, with a yearly average of -79.80%.

1: Adjusted price after possible price splits or reverse-splits.

Solid stock historical price chart

SLDB stock reached 52-week highs on September at $54.54, and all-time highs 2018-06-19 with a price of 54.84.

Solid stock price target is $10.50

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' SLDB stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 2 price targets for SLDB stock:
SLDB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-14Credit Suisse GroupDowngrades$7.00$6.00-14.3%
2019-2-7Chardan CapitalReiteratesn/a$15.00-
(in average)$7.00$10.5050.0%
The price target for Solid stock is $10.50, moving in a range between $15.00 and $6.00. In average, analysts' outlook on SLDB price forecast is positive, improving the prediction by a 50.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Solid Biosciences presented its financial report, posting a remarkable climb for the Earnings per Share (EPS) ratio. Analyst expected $-0.58 per share, but Solid posted $-0.67.
SLDB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-03-29-0.55-0.84n/a
2018-Q12018-05-10-0.43-0.54n/a
2018-Q22018-08-10-0.52-0.52n/a
2018-Q32018-11-13-0.55-0.55n/a
2018-Q42019-03-13-0.58-0.67n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to , last anual sales report draw of to million USD. , its profit margin (compared to revenues) to , that is million.

SLDB annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter earnings marked $-21.92 M with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Solid Biosciences sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, Solid posted 5 positive quarters in a row.
SLDB quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

Solid ownership

When you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Solid, 34.71% of all outstanding shares are owned by its staff.

In case of Solid Biosciences stock, 77.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SLDB stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related companies:

SLDB
Market cap$182.0 M
Total shares35.4 M
Float shares10.4 M
  - Institutional holdings (%)77.4%
  - Insider holdings (%)34.7%
Shares in short selling0.0%

Solid summary

Tuesday, July 16th, 2019
Open$5.25
Close$5.14
Day range$5.11 - $5.35
Previous close$5.25
Session gain-2.10%
Average true range$0.48
50d mov avg$5.86
100d mov avg$7.82
200d mov avg$18.03
Daily patternlt01a
Weekly pattern lt03a

Solid performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose as the bechmarking frame for Solid stock.
Stock3m6m12m
SLDBSolid Biosciences-44.19%-80.01%-88.08%

Solid competitors

Unfortunately, we could not find any public company that could be defined as Solid competitor. This doesn't mean Solid does not have any competitor in the market, it's just we could not detected it.